|
US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
|
US3567725A
(en)
|
1968-11-20 |
1971-03-02 |
Merck & Co Inc |
Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
|
|
US4317909A
(en)
|
1980-03-24 |
1982-03-02 |
Sterling Drug Inc. |
Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
|
|
US4294836A
(en)
|
1980-03-24 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
|
|
US4294837A
(en)
|
1980-03-28 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
|
|
US4309537A
(en)
|
1980-03-28 |
1982-01-05 |
Sterling Drug Inc. |
Production of imidazo[4,5-b]pyridin-2-ones or thiones
|
|
GB8709448D0
(en)
|
1987-04-21 |
1987-05-28 |
Pfizer Ltd |
Heterobicyclic quinoline derivatives
|
|
JPS63275582A
(ja)
|
1987-05-02 |
1988-11-14 |
Naade Kenkyusho:Kk |
２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
|
|
DD262026A1
(de)
|
1987-07-10 |
1988-11-16 |
Akad Wissenschaften Ddr |
Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
|
|
FR2643903A1
(fr)
|
1989-03-03 |
1990-09-07 |
Union Pharma Scient Appl |
Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
|
|
US4963561A
(en)
|
1990-02-28 |
1990-10-16 |
Sterling Drug Inc. |
Imidazopyridines, their preparation and use
|
|
TW274550B
(https=)
|
1992-09-26 |
1996-04-21 |
Hoechst Ag |
|
|
DE19601627A1
(de)
|
1996-01-18 |
1997-07-24 |
Bayer Ag |
Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
|
|
US6031105A
(en)
|
1996-04-09 |
2000-02-29 |
Pfizer Inc |
Substituted pyridines
|
|
NZ503432A
(en)
|
1997-09-26 |
2002-11-26 |
Zentaris Gmbh |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
|
CA2311414A1
(en)
|
1997-11-27 |
1999-06-10 |
Chugai Research Institute For Molecular Medicine, Inc. |
Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in lkb1 gene
|
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
|
JP2003146987A
(ja)
|
1999-05-31 |
2003-05-21 |
Dainippon Pharmaceut Co Ltd |
２−アリールプリン−９−アセトアミド誘導体
|
|
EP1186232A4
(en)
|
1999-05-31 |
2004-11-10 |
Chugai Pharmaceutical Co Ltd |
'KNOCKOUT' ANIMALS LACKING THE LKB1 GENE
|
|
JP3814125B2
(ja)
|
1999-06-02 |
2006-08-23 |
大日本住友製薬株式会社 |
２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
|
|
JP2002100363A
(ja)
|
2000-09-25 |
2002-04-05 |
Mitsubishi Chemicals Corp |
リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
|
|
JP2002167387A
(ja)
|
2000-11-29 |
2002-06-11 |
Dainippon Pharmaceut Co Ltd |
２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
|
|
BR0116113A
(pt)
|
2000-12-12 |
2004-08-03 |
Neurogen Corp |
Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas
|
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
PT1427730E
(pt)
|
2001-09-04 |
2006-11-30 |
Boehringer Ingelheim Pharma |
Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
|
|
EP1438048A1
(en)
|
2001-10-18 |
2004-07-21 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
|
TWI314928B
(en)
|
2002-02-28 |
2009-09-21 |
Novartis A |
5-phenylthiazole derivatives and use as pi3 kinase inhibitors
|
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
|
AU2003232071A1
(en)
|
2002-05-06 |
2003-11-17 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis c virus infection
|
|
WO2004042002A2
(en)
|
2002-08-05 |
2004-05-21 |
University Of Massachusetts |
Compounds for modulating rna interference
|
|
JP2006512313A
(ja)
|
2002-10-31 |
2006-04-13 |
アムジェン インコーポレイテッド |
抗炎症剤
|
|
US7423148B2
(en)
|
2002-11-21 |
2008-09-09 |
Chiron Corporation |
Small molecule PI 3-kinase inhibitors and methods of their use
|
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
BR0318145A
(pt)
|
2003-02-26 |
2006-02-21 |
Boehringer Ingelheim Pharma |
dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
|
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
|
EP2345657A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
|
CA2529196A1
(en)
|
2003-06-26 |
2005-02-17 |
Merck & Co., Inc. |
Benzodiazepine cgrp receptor antagonists
|
|
GB0315259D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Cyclacel Ltd |
Use
|
|
DE602004013160T2
(de)
|
2003-07-17 |
2009-07-02 |
University Of Dundee, Dundee |
Verfahren zur anwendung eines an lkb1/strad/mo25-komplexes
|
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
|
US20080194019A1
(en)
|
2003-09-09 |
2008-08-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
|
|
CA2569406A1
(en)
|
2004-06-04 |
2005-12-22 |
Icos Corporation |
Methods for treating mast cell disorders
|
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
WO2006001266A1
(ja)
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
２－アリールプリン誘導体の製造方法
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
WO2006036883A2
(en)
|
2004-09-24 |
2006-04-06 |
Janssen Pharmaceutica, N.V. |
Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
|
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
|
AU2005298637B8
(en)
|
2004-10-29 |
2012-12-06 |
Janssen Sciences Ireland Uc |
HIV inhibiting bicyclic pyrimidine derivatives
|
|
US7855205B2
(en)
|
2004-10-29 |
2010-12-21 |
Janssen Pharmaceutica Nv |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
|
SE0403006D0
(sv)
|
2004-12-09 |
2004-12-09 |
Biovitrum Ab |
New compounds
|
|
AU2005316668B2
(en)
|
2004-12-13 |
2012-09-06 |
Millennium Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
|
PT1853588E
(pt)
|
2005-02-16 |
2008-08-25 |
Astrazeneca Ab |
Compostos químicos
|
|
WO2006091737A1
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
|
AU2006217742A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
|
|
AU2006217744A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors
|
|
NZ562468A
(en)
|
2005-04-05 |
2009-10-30 |
Pharmacopeia Inc |
Purine and imidazopyridine derivatives for immunosuppression
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
US8247408B2
(en)
|
2005-10-07 |
2012-08-21 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
|
|
CN101395155A
(zh)
|
2005-10-07 |
2009-03-25 |
埃克塞里艾克西斯公司 |
PI3Kα的吡啶并嘧啶酮抑制剂
|
|
EP1946120A2
(en)
|
2005-10-18 |
2008-07-23 |
George Mason Intellectual Properties, Inc. |
Mtor pathway theranostic
|
|
EP2385053B1
(en)
|
2005-11-17 |
2013-10-02 |
OSI Pharmaceuticals, Inc. |
Intermediates for the preparation of fused bicyclic mTOR inhibitors
|
|
PL1954699T3
(pl)
|
2005-11-22 |
2013-01-31 |
Kudos Pharm Ltd |
Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
|
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0525083D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2009523161A
(ja)
|
2006-01-11 |
2009-06-18 |
アストラゼネカ アクチボラグ |
モルホリノピリミジン誘導体と療法におけるその使用
|
|
US20090281075A1
(en)
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
|
WO2007125321A2
(en)
|
2006-04-25 |
2007-11-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
US20090118336A1
(en)
|
2006-05-03 |
2009-05-07 |
Laurent David |
Pyrazole derivatives and their use as pi3k inhibitors
|
|
EP2016075A1
(en)
|
2006-05-03 |
2009-01-21 |
AstraZeneca AB |
Thiazole derivatives and their use as anti-tumour agents
|
|
WO2007135398A1
(en)
|
2006-05-22 |
2007-11-29 |
Astrazeneca Ab |
Indole derivatives
|
|
ES2558517T3
(es)
|
2006-08-02 |
2016-02-04 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
|
|
KR101438245B1
(ko)
|
2006-08-23 |
2014-09-04 |
쿠도스 파마슈티칼스 리미티드 |
Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
|
|
WO2008030744A2
(en)
|
2006-09-05 |
2008-03-13 |
Board Of Regents, The University Of Texas System |
Inhibitors of c-met and uses thereof
|
|
US8268809B2
(en)
|
2006-09-05 |
2012-09-18 |
Emory University |
Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
|
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
EP2069330A1
(en)
|
2006-09-14 |
2009-06-17 |
AstraZeneca AB |
2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
CN101595103A
(zh)
|
2006-09-14 |
2009-12-02 |
阿斯利康(瑞典)有限公司 |
嘧啶衍生物
|
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032072A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
TW200831104A
(en)
|
2006-10-04 |
2008-08-01 |
Pharmacopeia Inc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
US7968556B2
(en)
|
2006-10-19 |
2011-06-28 |
Signal Pharmaceuticals, Llc |
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
|
|
ATE543819T1
(de)
*
|
2006-10-19 |
2012-02-15 |
Signal Pharm Llc |
Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
|
|
RS53335B
(sr)
|
2006-11-20 |
2014-10-31 |
Novartis Ag |
Kristalna monotozilatna so 2-metil-2-[4-(3-metil-2-okso-8-hinolin-3-il-2,3-dihidro-imidazo[4,5-c]hinolin-1-il)-fenil]-propionitrila
|
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
|
CN101809002B
(zh)
|
2007-07-09 |
2013-03-27 |
阿斯利康(瑞典)有限公司 |
用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
|
|
CA2692945A1
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Compounds - 945
|
|
WO2009007751A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
US8129371B2
(en)
|
2007-10-16 |
2012-03-06 |
Wyeth Llc |
Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
|
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
WO2009091788A1
(en)
|
2008-01-15 |
2009-07-23 |
Wyeth |
3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
US20110091574A1
(en)
|
2008-02-15 |
2011-04-21 |
Catholic Healthcare West |
Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
CA2744498C
(en)
|
2008-11-25 |
2017-10-24 |
University Of Rochester |
Mlk inhibitors and methods of use
|
|
NO2477987T3
(https=)
|
2009-09-14 |
2018-06-09 |
|
|
|
MY177695A
(en)
|
2009-10-26 |
2020-09-23 |
Signal Pharm Llc |
Methods of synthesis and purification of heteroaryl compounds
|
|
US8541418B2
(en)
|
2009-12-23 |
2013-09-24 |
Elan Pharmaceutical, Inc. |
Inhibitors of polo-like kinase
|
|
EP2531194B1
(en)
|
2010-02-03 |
2018-04-18 |
Signal Pharmaceuticals, LLC |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
US20110318336A1
(en)
|
2010-03-29 |
2011-12-29 |
George Mason Intellectual Properties, Inc. |
Identification and Treatment of Aggressive Lung Cancer Tumors
|
|
US20120028972A1
(en)
*
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
|
CA2843887A1
(en)
|
2011-08-03 |
2013-02-07 |
Signal Pharmaceuticals, Llc |
Identification of gene expression profile as a predictive biomarker for lkb1 status
|
|
KR101978537B1
(ko)
|
2011-10-19 |
2019-05-14 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제제를 사용한 암의 치료
|
|
JP6076370B2
(ja)
|
2011-12-02 |
2017-02-08 |
シグナル ファーマシューティカルズ，エルエルシー |
７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法
|
|
TWI615143B
(zh)
|
2012-02-24 |
2018-02-21 |
標誌製藥公司 |
使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
|
|
EA028434B1
(ru)
|
2012-03-15 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Лечение рака ингибиторами tor киназы
|
|
CA2866872A1
(en)
|
2012-03-15 |
2013-09-19 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with tor kinase inhibitors
|
|
UA114194C2
(uk)
|
2012-03-15 |
2017-05-10 |
Сігнал Фармасьютікалз, Елелсі |
Лікування раку інгібітором тоr кінази
|
|
WO2013138553A1
(en)
|
2012-03-15 |
2013-09-19 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with tor kinase inhibitors
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
BR112015026297B1
(pt)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
|
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
|
|
AU2014254052B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
BR112015026292B1
(pt)
*
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
|
US9782427B2
(en)
|
2013-04-17 |
2017-10-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
|
CN105358177B
(zh)
|
2013-04-17 |
2018-11-23 |
西格诺药品有限公司 |
包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
|
|
US9937169B2
(en)
|
2013-04-17 |
2018-04-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
|
|
US20140314673A1
(en)
*
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
TW201527300A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
|
|
NZ714742A
(en)
*
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|